Among the best investments ever made in a technology has been the ability to sequence, annotate, and make functional associations of genes for therapeutic indications – in short, the whole field of genomics and precision medicine. We see the pay-off today in the rapid sequencing of the SARS Cov-2 RNA genome, the rapid development of vaccines, and the current tracking of the coronavirus variants in near-real time. While genomics continues to play a role for developing effective, targeted drugs for cancers, its impact has been expanding to impact other therapeutic areas and diseases with a new generation of assays and medicines for personalized therapeutic regimens.
Steve Gardner will present how the PrecisionLife platform enables the high resolution stratification of patient populations to improve our understanding of disease biology based on genomic and other data, and identification of new targets and risk scores. he will exemplify the precision medicine opportunity through a discussion of understanding risk of diabetes complication and Alzheimers disease.